Acotec Scientific Holdings Limited (7W3) Stock Price & Analysis
7W3 Stock Chart & Stats
- Day’s Range
- EUR 0.58 - EUR 0.58
- 52-Week Range
- EUR 0.57 - EUR 1.59
- Previous Close
- EUR 0.58
- Volume
- 184
- Average Volume (3M)
- 0
- Market Cap
- EUR 186.07M
- Enterprise Value
- EUR 1.71B
- Total Cash (Recent Filing)
- EUR 806.80M
- Total Debt (Recent Filing)
- EUR 193.70M
- Price to Earnings (P/E)
- ―
- Beta
- 0.68
- Next Earnings
- Mar 29, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved Profitability
The sharp improvement in net margin, alongside a very strong gross margin, indicates better operating leverage and/or cost control. If maintained, this profitability provides greater capacity to fund product development, expand hospital adoption, and convert revenue growth into durable earnings.
Stronger Cash Generation
Strong operating and free cash flow in 2025 shows that reported earnings were supported by substantial cash conversion. This improves the company’s ability to finance growth internally, support commercial expansion, and withstand normal fluctuations in hospital purchasing and procedure volumes.
Conservative Leverage
Modest leverage and a substantial equity base give Acotec greater financial flexibility than a highly indebted medical-device company. A relatively light debt burden can reduce financing pressure and leave more capacity for investment in vascular products, clinical adoption, and market expansion.
Bears Say
Historical Earnings Volatility
The recovery in 2025 has not yet demonstrated consistent performance across the full cycle. Earlier losses and the sharp 2023 earnings decline suggest that profitability can vary materially, making future earnings power less dependable and increasing the risk that recent margin gains are not fully structural.
Uneven Cash Flow Track Record
Although cash generation improved substantially in 2025, the prior negative cash-flow years and the latest year-on-year FCF decline point to inconsistent conversion through the cycle. This can make internally funded expansion less predictable and complicate capital allocation when operating conditions weaken.
Gross-Margin Normalization
A gross margin near 72% remains strong, but its decline from earlier unusually high levels indicates that some historical profitability advantage has moderated. Continued normalization could limit operating leverage and reduce the amount of revenue growth that flows through to earnings and cash generation.
Acotec Scientific Holdings Limited News
7W3 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
What is Acotec Scientific Holdings Limited’s market cap?
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Is Acotec Scientific Holdings Limited overvalued?
Does Acotec Scientific Holdings Limited pay dividends?
What is Acotec Scientific Holdings Limited’s EPS estimate?
How many shares outstanding does Acotec Scientific Holdings Limited have?
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jing Li
- Employees
- 955
- Website
- www.acotec.cn
- Address
- Building No. 1, Beijing, BE, 100176, CN
Acotec Scientific Holdings Limited (7W3) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |